DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $475,898 | +2.8% | 1,793 | 0.0% | 0.42% | -0.7% |
| Q3 2022 | $463,000 | +1.8% | 1,793 | 0.0% | 0.42% | +7.6% |
| Q2 2022 | $455,000 | -13.5% | 1,793 | 0.0% | 0.39% | +4.2% |
| Q1 2022 | $526,000 | -10.8% | 1,793 | 0.0% | 0.38% | -5.3% |
| Q4 2021 | $590,000 | +8.1% | 1,793 | 0.0% | 0.40% | +0.8% |
| Q3 2021 | $546,000 | +13.5% | 1,793 | 0.0% | 0.40% | +14.8% |
| Q2 2021 | $481,000 | +19.1% | 1,793 | 0.0% | 0.34% | +12.8% |
| Q1 2021 | $404,000 | +1.5% | 1,793 | 0.0% | 0.30% | -4.1% |
| Q4 2020 | $398,000 | +3.1% | 1,793 | 0.0% | 0.32% | -8.9% |
| Q3 2020 | $386,000 | -99.9% | 1,793 | +0.1% | 0.35% | +12.6% |
| Q2 2020 | $316,703,000 | +124586.2% | 1,791 | -2.5% | 0.31% | +6.2% |
| Q1 2020 | $254,000 | -3.1% | 1,837 | +7.5% | 0.29% | +28.1% |
| Q4 2019 | $262,000 | -29.4% | 1,709 | -33.5% | 0.23% | -27.8% |
| Q3 2019 | $371,000 | -14.9% | 2,571 | -15.8% | 0.32% | -14.6% |
| Q2 2019 | $436,000 | +8.2% | 3,053 | 0.0% | 0.37% | +9.5% |
| Q1 2019 | $403,000 | +27.9% | 3,053 | 0.0% | 0.34% | +6.0% |
| Q4 2018 | $315,000 | -7.9% | 3,053 | -3.0% | 0.32% | +16.0% |
| Q3 2018 | $342,000 | +54.1% | 3,148 | +40.0% | 0.28% | +44.0% |
| Q2 2018 | $222,000 | +7.2% | 2,248 | +6.4% | 0.19% | +2.7% |
| Q1 2018 | $207,000 | – | 2,113 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |